Donald M. Miller, M.D., Ph.D.

Donald M. Miller, M.D., Ph.D. Professor of Medicine and Pharmacology Chief, Division of Medical Oncology and Hematology Director, James Graham Brown Cancer Center James Graham Brown Foundation Chair James Graham Brown Cancer Center 530 South Jackson Street Louisville, KY 40202 502-852-2522 - Academic Office 502-562-4370 - Patient Appointments

Clinical Expertise

Head and Neck; Medical Oncology; Skin Cancer; Melanoma

Board Certifications

• American Board of Internal Medicine - Internal Medicine

Education and Training

• Medical School: Duke University

• Residency: Peter Bent Brigham Hospital, Boston Mass.

• Fellowship: Harvard University

Recent Publications

• Sedoris KC, Thomas SD, Clarkson CR, Muench D, Islam A, Singh R, Miller DM. Genomic c-Myc quadruplex DNA selectively kills leukemia. Mol Cancer Ther. 2012 Jan;11(1):66-76. Epub 2011 Nov 14.

• Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer. 2011 Dec 13;11:515.

• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 2;364(22):2119-27.

• Lane AN, Fan TW, Bousamra M 2nd, Higashi RM, Yan J, Miller DM. Stable isotope-resolved metabolomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer. OMICS. 2011 Mar;15(3):173-82. Epub 2011 Feb 17. Review.

• Sedoris KC, Thomas SD, Miller DM. Hypoxia induces differential translation of enolase/MBP-1. BMC Cancer. 2010 Apr 22;10:157.

• Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA. Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck. Am J Med Sci. 2010 Feb;339(2):148-51.

• Desai PC, Jaglal MV, Gopal P, Ghim SJ, Miller DM, Farghaly H, Jenson AB. Human papillomavirus in metastatic squamous carcinoma from unknown primaries in the head and neck: a retrospective 7 year study. Exp Mol Pathol. 2009 Oct;87(2):94-8.Epub 2009 Apr 22.

• Jaglal MV, Laber DA, Arnold FW, Miller DM, Chesney JA, Kloecker GH. Obtaining routine blood cultures during interleukin-2-containing therapy is unnecessary. Am J Clin Oncol. 2009 Aug;32(4):429-31.

• Fan TW, Lane AN, Higashi RM, Bousamra M 2nd, Kloecker G, Miller DM. Metabolic profiling identifies lung tumor responsiveness to erlotinib. Exp Mol Pathol. 2009 Aug;87(1):83-6. Epub 2009 May 3.

• Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009 Jun 26;8:41.